Coloma Jason V 4

What Happened
Jason V. Coloma, CEO of Maze Therapeutics (MAZE), sold a total of 32,564 shares in open-market dispositions across May 22 and May 26, 2026, generating proceeds of about $847,048. Sales reported: 4,504 shares at $26.00 ($117,104), 2,478 shares at $26.00 ($64,428), and 25,582 shares at a weighted average $26.02 ($665,516). At least one of the transactions was effected under a Rule 10b5-1 trading plan adopted Feb 6, 2026.

Key Details

• Transaction dates: May 22, 2026 (two disposals); May 26, 2026 (one disposal). Form filed May 27, 2026.
• Prices: two May 22 disposals reported at $26.00; May 26 disposal WAP $26.02. Footnotes indicate sale prices ranged roughly $26.00–$26.105 per share across multiple executions.
• Total shares sold: 32,564; total proceeds reported: $847,048.
• Holdings after the transactions: not specified in the supplied excerpt (see the full Form 4 for post-transaction holdings).
• Notable footnotes: at least one sale under a Rule 10b5-1 plan (F1); sales executed in multiple trades with weighted-average pricing and listed price ranges (F2, F5); some securities are held by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Coloma and his spouse are co-trustees (F3, F4). The filer offers to provide breakdowns of shares sold at each price upon request.

Context
These were sales (not purchases). Sales executed under a pre-established 10b5-1 plan are commonly scheduled in advance and are considered routine; they do not, by themselves, indicate management’s view of the company’s prospects. For full detail on holdings after the trades or the precise per-trade prices, consult the complete Form 4 filing (Accession 0001676170-26-000007).